These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24516013)

  • 1. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
    Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
    J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
    Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
    Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
    Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
    Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
    Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
    J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
    Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
    J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
    Al-Mansour M; Connors JM; Gascoyne RD; Skinnider B; Savage KJ
    J Clin Oncol; 2010 Feb; 28(5):793-9. PubMed ID: 20048177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
    Advani RH; Hoppe RT
    Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
    Fanale MA; Cheah CY; Rich A; Medeiros LJ; Lai CM; Oki Y; Romaguera JE; Fayad LE; Hagemeister FB; Samaniego F; Rodriguez MA; Neelapu SS; Lee HJ; Nastoupil L; Fowler NH; Turturro F; Westin JR; Wang ML; McLaughlin P; Pinnix CC; Milgrom SA; Dabaja B; Horowitz SB; Younes A
    Blood; 2017 Jul; 130(4):472-477. PubMed ID: 28522441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
    Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
    J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
    Mocikova H; Pytlik R; Stepankova P; Michalka J; Markova J; Koren J; Buresova L; Raida L; Kral Z
    Acta Haematol; 2015; 134(3):187-92. PubMed ID: 26021284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in lymphocyte-predominant Hodgkin disease.
    Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
    Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
    Biasoli I; Stamatoullas A; Meignin V; Delmer A; Reman O; Morschhauser F; Coiffier B; Bosly A; Diviné M; Brice P
    Cancer; 2010 Feb; 116(3):631-9. PubMed ID: 20029973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.